

neuropad® for South Korea

TISSUPOR has signed an exclusive Distribution Agreement with CJ Corp. for South Korea

We are very proud to announce that we have signed the final agreement granting CJ Corp. the exclusive License and Distribution rights for neuropad[®], an early detection plaster predicting the potential for developing Diabetic Foot Syndrome (DFS), in the Republic of Korea.




CJ Corp. is the largest food, pharmaceutical and entertainment company with headquarters in South Korea. The company was established as the first manufacturing operation unit of the Samsung Group in 1953, and since then, it has diversified its portfolio to pharmaceuticals, entertainment business, etc.

We are very pleased with this new milestone in our worldwide licensing activity and we look forward to working very closely with CJ Corp. for the registration of neuropad[®] in Korea and also for other foreign countries. We believe that CJ Corp. has the best knowledge and experience to commercialize

the product successfully.

"CJ Corp. is so glad to bring a novel diagnostic product to help the Korean diabetic predict the potential DFS and maintain healthy feet," said Dr. Kil-Whan Chun, Executive Vice President of CJ Corp. "With this new agreement, CJ Corp. is going to demonstrate its strong commitment to the antidiabetes community in Korea."



neuropad[®] looks like any other ordinary dressing, but it detects the potential for developing DFS by measuring the hydro status of the foot. The function of the perspiratory glands is vital for the elasticity and healthy function of the foot bed. The malfunction of these glands is the primary indication of the potential development of DFS and can now be detected before clinical symptoms occur. The early prediction of DFS therefore allows adoption of effective prophylactic treatment. The effectivenesss of neuropad[®] has been documented by clinical studies.

neuropad[®], an innovative, simple and economic solution for early detection has been invented by Professor Zick in the diabetics field and has been developed in cooperation with miro Verbandstoffe GmbH, Germany.



From left to right: Dr. Y. S. Lee (Senior Manager BD, CJ Europe), K. Bischoff (Export Manager, TISSUPOR), Dr. K. W. Chun (President Pharmaceutical Div., CJ. Corp.) Dr. M. F. Billia (Managing Director, TISSUPOR), S. Rothmann (CEO Deputy, miro Verbandstoffe), Dr. Y. H. Lee (Director Pharmaceutical BD, CJ Corp.), G. Jakob (CEO Assistance, miro Verbandstoffe)